The following condition (A) arthritis, especially bone arthropathy and inflammation characteristic arthropathy (B) the cartilage formation promotion in the mammal (Cell multiplication promotion of c) cartilage cell (D) production of gurikosaminogurikan in the mammal It used for the disposal which and (e) it chose from the group which the reduction of symptom of the mobility which joint it is stiffened and is limited and consists of, in the mammal, next formula (i) (however R is the alkyl group of formula C nH2n+1, n is chosen from 2 - 12) the 2- gurukosuamin derivative And the salt which on this medicine manufacture it can allow, ester and glucoside.次の症状;(a)関節炎、特に骨関節症及び炎症性関節症;(b)哺乳動物における軟骨形成促進;(c)軟骨細胞の細胞増殖促進;(d)哺乳動物におけるグリコサミノグリカンの生産;及び(e)関節硬直及び限定された可動性の症候の軽減よりなる群から選んだ、哺乳動物における処置に用いた、次式(I)(但しRは式CnH2n+1のアルキル基であり、nは2~12から選ばれる)の2-グルコスアミン誘導体;及びこれの製薬上許容しうる塩、エステル及びグルコシド。
